Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
NTRA — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

3.15

Margin Of Safety %

-37

Put/Call OI Ratio

0.64

EPS Next Q Diff

0.24

EPS Last/This Y

-0.16

EPS This/Next Y

1.47

Price

260.91

Target Price

263.62

Analyst Recom

1.42

Performance Q

33.53

Upside

-121.9%

Beta

1.48

Ticker: NTRA




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-29NTRA223.370.680.1726905
2026-06-02NTRA212.580.650.7228291
2026-06-03NTRA212.050.661.0828353
2026-06-04NTRA222.10.660.4528392
2026-06-05NTRA215.30.660.8728939
2026-06-08NTRA213.40.670.5829265
2026-06-09NTRA222.450.670.7529410
2026-06-10NTRA216.890.672.1129629
2026-06-11NTRA219.350.671.1129548
2026-06-12NTRA212.220.671.1929601
2026-06-15NTRA216.960.670.2229591
2026-06-16NTRA220.310.660.5829710
2026-06-17NTRA226.560.670.3130023
2026-06-18NTRA231.170.670.2230979
2026-06-22NTRA228.970.641.7528101
2026-06-23NTRA234.830.660.2828460
2026-06-24NTRA259.990.690.1728730
2026-06-25NTRA260.580.590.6732626
2026-06-26NTRA261.240.640.1832008
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-29NTRA223.2332.2-4.8-1.66
2026-06-01NTRA218.5532.213.6-1.66
2026-06-02NTRA213.2332.214.3-1.66
2026-06-03NTRA211.8932.28.6-1.66
2026-06-04NTRA221.9332.2-5.9-1.66
2026-06-05NTRA215.1429.616.3-1.70
2026-06-08NTRA213.4929.69.9-1.70
2026-06-09NTRA222.8729.3-5.0-1.68
2026-06-10NTRA216.5229.315.5-1.68
2026-06-11NTRA219.4229.33.7-1.68
2026-06-12NTRA212.1129.316.6-1.68
2026-06-15NTRA216.9329.31.0-1.68
2026-06-16NTRA220.3129.63.1-1.68
2026-06-17NTRA226.5229.6-0.7-1.68
2026-06-18NTRA231.4329.61.3-1.68
2026-06-22NTRA228.9429.610.5-1.68
2026-06-23NTRA234.7629.60.1-1.68
2026-06-24NTRA259.9529.6-22.8-1.68
2026-06-25NTRA260.7629.66.6-1.68
2026-06-26NTRA260.9129.67.3-1.68
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-29NTRA-9.392.532.77
2026-06-02NTRA-9.391.722.77
2026-06-03NTRA-9.391.722.77
2026-06-04NTRA-10.291.722.77
2026-06-05NTRA-10.291.722.77
2026-06-08NTRA-10.781.692.77
2026-06-09NTRA-10.901.692.77
2026-06-10NTRA-10.981.692.65
2026-06-11NTRA-10.981.692.65
2026-06-12NTRA-10.981.692.65
2026-06-15NTRA-11.131.672.64
2026-06-16NTRA-11.131.672.64
2026-06-17NTRA-11.701.672.64
2026-06-18NTRA-11.741.672.64
2026-06-22NTRA-11.741.692.64
2026-06-23NTRA-11.851.692.64
2026-06-24NTRA-11.851.692.64
2026-06-25NTRA-11.851.692.64
2026-06-26NTRA-11.831.693.15
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.6

Avg. EPS Est. Current Quarter

-0.52

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-11.83

Institutional Transactions

1.69

Beta

1.48

Average Sales Estimate Current Quarter

661

Average Sales Estimate Next Quarter

694

Fair Value

164.63

Quality Score

49

Growth Score

58

Sentiment Score

94

Actual DrawDown %

3.9

Max Drawdown 5-Year %

-77.7

Target Price

263.62

P/E

Forward P/E

PEG

P/S

15

P/B

21.07

P/Free Cash Flow

358.91

EPS

-1.64

Average EPS Est. Cur. Y​

-1.68

EPS Next Y. (Est.)

-0.21

Target Price Estimates Raised

1

Target Price Estimates Lowered

1

Profit Margin

-9.05

Relative Volume

2.27

Return on Equity vs Sector %

-40.1

Return on Equity vs Industry %

-23.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

7.3
NTRA Healthcare
$261.91
📉
Swing / Pullback
Buy the dip on strong trends
31 /100
WEAK
Trend
14/20
Pullback
6/25
Volume
3/15
Valuation
1/20
TP/AR
2/10
Options
5/10
RSI
73.4
Range 1M
87.2%
Sup Dist
2.4%
🚀
Momentum Growth
Ride accelerating trends
52 /100
WEAK
Momentum
20/25
Growth
13/30
Estimates
2/20
Inst/Vol
10/15
Options
7/10
EPS Yr
-6.3%
EPS NY
81.3%
52W%
93.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -22% upside
Quality
6/30
Valuation
0/30
Growth
8/25
Stability
8/10
LT Trend
4/5
Upside
-22%
Quality
49
MoS
-37%
NTRA — P/E HistoricalDiagnostics & Research
Natera, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 6135
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
NTRA

Latest News

Caricamento notizie per NTRA
stock quote shares NTRA – Natera, Inc. Stock Price stock today
news today NTRA – Natera, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTRA – Natera, Inc. yahoo finance google finance
stock history NTRA – Natera, Inc. invest stock market
stock prices NTRA premarket after hours
ticker NTRA fair value insiders trading